• 1. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

Introduction to (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate (CAS No. 394653-41-9)

(R)-Methyl 2-amino-2-(oxetan-3-yl)acetate, a compound with the chemical identifier CAS No. 394653-41-9, is a significant molecule in the field of chiral chemistry and pharmaceutical research. This compound belongs to the class of oxetane derivatives, which are known for their unique structural and functional properties. The presence of a stereocenter at the (R)-configuration makes it a valuable building block for the synthesis of enantiomerically pure pharmaceuticals and agrochemicals.

The oxetane ring in (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate introduces a high degree of conformational rigidity, which can be exploited to design molecules with specific biological activities. This structural feature has garnered considerable attention in recent years, particularly in the development of novel drug candidates. The compound's ability to serve as a precursor in the synthesis of more complex molecules has made it a topic of interest for synthetic chemists and medicinal chemists alike.

In recent years, there has been a growing emphasis on the use of chiral auxiliaries and catalysts in asymmetric synthesis. (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate has been employed in various catalytic processes to achieve high enantioselectivity in the formation of biologically active molecules. For instance, its application in transition metal-catalyzed reactions has led to the development of efficient synthetic routes for complex natural products and pharmacologically relevant compounds.

The pharmaceutical industry has been particularly interested in oxetane derivatives due to their potential as pharmacophores. (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate has been investigated as a key intermediate in the synthesis of drugs targeting various therapeutic areas, including central nervous system disorders, inflammation, and metabolic diseases. Its incorporation into drug molecules has been shown to enhance binding affinity and reduce side effects, making it a promising candidate for further development.

One of the most exciting applications of (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate is in the field of protease inhibition. Proteases are enzymes that play crucial roles in many biological processes, and their inhibition is often a key strategy in drug design. Researchers have utilized this compound as a scaffold to develop inhibitors targeting specific proteases involved in diseases such as cancer and infectious diseases. The oxetane ring's rigidity helps stabilize the transition state during catalysis, making it an effective tool for designing potent inhibitors.

Another area where (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate has shown promise is in the development of chiral ligands for asymmetric catalysis. Chiral ligands are essential for achieving enantioselective transformations, which are critical for producing pharmaceuticals with high enantiomeric purity. The oxetane derivative's unique steric environment allows it to interact selectively with transition metals, facilitating highly enantioselective reactions that would otherwise be challenging to achieve.

The synthesis of (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate involves several key steps that highlight its importance as a synthetic intermediate. The process typically begins with the preparation of an oxetane precursor, which is then functionalized to introduce the amino and ester groups. The stereochemistry at the chiral center is carefully controlled using chiral auxiliaries or catalysts to ensure high enantiomeric purity. This synthesis showcases the compound's versatility and utility in constructing complex molecules.

Recent advancements in computational chemistry have also contributed to the understanding and optimization of (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate's properties. Molecular modeling studies have provided insights into its interactions with biological targets, helping researchers design more effective drug candidates. These computational approaches have been particularly useful in predicting binding affinities and identifying potential lead compounds for further optimization.

In conclusion, (R)-Methyl 2-amino-2-(oxetan-3-yl)acetate (CAS No. 394653-41-9) is a versatile and valuable compound with significant applications in pharmaceutical research and chemical synthesis. Its unique structural features make it an excellent precursor for developing enantiomerically pure drugs targeting various diseases. As research continues to uncover new applications for this compound, its importance in the chemical and pharmaceutical industries is likely to grow even further.

• 394653-40-8(methyl 2-[(oxetan-3-yl)amino]acetate)
• 4070-48-8(L-valine methyl ester)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)